This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Glaukos Stock Soars 77.9% Year to Date: What's Behind the Rally?
by Zacks Equity Research
GKOS stock gains from strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.
GEHC Stock Likely to Gain on Portrait Mobile Solution's Prospects
by Zacks Equity Research
GE HealthCare's Portrait Mobile solution will provide continuous monitoring in post-surgery settings. It will also deliver informative alarms, advancing patient care while alleviating the burdens faced by clinicians.
HealthEquity Gains 54.6% YTD: What's Driving the Stock?
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
Stryker Stock May Gain From Oculan Lighting Platform's Launch
by Zacks Equity Research
SYK launches the Oculan Lighting Platform to improve lighting conditions in the operating rooms and allow surgeons to perform with more accuracy.
NVRO Stock Declines Despite Positive Study Data of Nevro1 System
by Zacks Equity Research
Nevro unveils publication of positive data study regarding its Nevro1 SI Joint Fusion System.
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
by Zacks Equity Research
WST continues to gain momentum due to its strength in the Pharma market unit. However, decline across its Generics and Biologics business units is concerning.
INBS Stock Declines Despite Positive Results of Pharmacokinetic Study
by Zacks Equity Research
Intelligent Bio Solutions unveils strong initial results for its PK study, which is important for FDA submission of its Intelligent Fingerprinting Drug Screening System.
LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint
by Zacks Equity Research
LIVN's aura6000 significantly increases responder rates. The device also reduces AHI and ODI levels. A premarket approval application will be filed soon.
SYK Stock Rises Following the Launch of Next Generation SurgiCount+
by Zacks Equity Research
Stryker launches the next generation of SurgiCount+ to boost sponge management and blood loss assessment in hospitals.
GE HealthCare and DeepHealth Collaborate to Advance AI in Imaging
by Zacks Equity Research
GEHC and DeepHealth collaborate to develop AI-based imaging tools that can streamline workflow and help manage large imaging volumes without compromising diagnostic accuracy.
SOLV Stock Falls Despite Launch of Clarity Precision Grip Attachments
by Zacks Equity Research
Solventum's Clarity precision grip attachments enhance treatment outcomes for orthodontic patients, reducing the risk of misplaced and malformed attachments.
GEHC Stock Falls Despite FDA Clearance for SIGNA MAGNUS MRI System
by Zacks Equity Research
GE Healthcare receives FDA clearance for its head-only SIGNA MAGNUS 3.0T MRI System.
Here's Why You Should Add HealthEquity Stock to Your Portfolio Now
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
Cardinal Health Stock Gains Following Two Strategic Acquisitions
by Zacks Equity Research
CAH announces two strategic acquisitions to strengthen its multi-specialty and at-Home Solutions businesses.
Reasons to Retain Veeva Systems Stock in Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio raises optimism about the stock. However, stiff competition and escalating costs are concerning.
Integer Holdings Gains 40.8% YTD: What's Driving the Stock?
by Zacks Equity Research
ITGR shares gain on the back of growth in the Medical segment. However, fluctuations in the oil and energy market are concerning.
Nevro Stock Rises on Q3 Earnings Beat, Revenues Decrease Y/Y
by Zacks Equity Research
NVRO's third-quarter earnings beat its Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level.
BRKR Stock Declines Despite Launching EpicIF Technology for CellScape
by Zacks Equity Research
Bruker's new technology, EpicIF, is set to enhance the CellScape Precise Spatial Proteomics platform.
Reasons to Add The Cooper Companies Stock to Your Portfolio Now
by Zacks Equity Research
COO benefits from strength in its business segments. Its acquisitions are likely to drive the top line. However, a rise in selling, general and administrative expenses is concerning.
QuidelOrtho Stock Rises as Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
QDEL's third-quarter results reflect growth in non-respiratory revenues along with a lowering of operating expenses year over year. However, the gross margin declines in the reported quarter.
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y
by Zacks Equity Research
PacBio Q3 2024 revenues decline year over year. However, Consumable, and Service and other revenues increase.
BAX Stock Falls Despite Q3 Earnings & Sales Beat, Margins Decline
by Zacks Equity Research
Baxter reports better-than-expected third-quarter results. However, the company's gross and operating margins contract. Shares fall.
SOLV Stock Gains as Q3 Earnings & Sales Beat Estimates, '24 View Up
by Zacks Equity Research
Solventum's top line reflects the favorable impact of pricing normalization. Organic growth is primarily driven by rising demand for MedSurg products. The higher EPS outlook looks promising.
XRAY Q3 Earnings & Revenues Beat Estimates, 2024 Guidance Revised
by Zacks Equity Research
DENTSPLY SIRONA's third-quarter results showcase strong top-line growth in the Essential Dental Solutions segment. However, the lowered outlook for fiscal 2024 is a cause of concern.
MCK Stock Gains as Q2 Earnings & Sales Top Estimates, '25 EPS View Up
by Zacks Equity Research
McKesson's second-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.